Theorem Clinical Research and Decision Driver Analytics Form Strategic Alliance
Theorem Clinical Research has announced the formation of a strategic alliance with Decision Driver Analytics
Theorem Clinical Research
has announced the formation of a strategic alliance with
Decision Driver Analytics
(DDA) that will integrate health economics and outcomes research (HEOR), predictive modeling and definitive analysis to maximize return on investment for pharmaceutical and medical device research programs.
“The clinical studies that may prove a scientific point are really only one aspect of a successful drug or medical device development program,” said
John Potthoff, president and CEO of Theorem Clinical Research
. “Decision Driver Analytics’ product life cycle value analysis and exceptional economic insight help clients make high-value decisions with confidence throughout the entire development process.”
Decision Driver Analytics was founded in 2006 by Elizabeth Brooks, Ph.D., to provide accessible health economics analysis and strategies that can be used to drive key product decisions for manufacturers and developers. A recognized expert in her field, Brooks has designed numerous health economics models and market development programs. Backed by a team of specialists including health economists, epidemiologists, biostatisticians, medical writers and reimbursement experts, Brooks is known for an ability to make statistical results understandable and actionable.
“Knowing the right answers to key questions at critical decision points in the development process can make the difference between having the latest blockbuster or an expensive failure,” Potthoff said. “We believe this alliance helps drive projects for clients in ways that will achieve both regulatory and marketing success.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
